Dr. Ledermann Discusses Patient Selection in Ovarian Cancer
Jonathan Ledermann, MD
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.
It is important to delineate which patients benefit from BRCA-targeting agents. This is not only to keep costs down, but to ensure that the patients receiving the drug will derive the most benefit, Ledermann says.